The Company's Board of Director's resolution on
issung 2nd domestic unsecured convertible corporate bonds
Date of events
2022/06/14
To which item it meets
paragraph 11
Statement
1.Date of the board of directors resolution:2022/06/14
2.Name [issue no.__ of (secured, unsecured) corporate
bonds of ___________ (company)]:Bora Pharmaceuticals
2nd domestic unsecured convertible corporate bonds
3.Whether to adopt shelf registration(Yes/No):No
4.Total amount issued:Up to NTD 800 million
5.Face value per bond:NTD 100 thousand
6.Issue price:Through auction, and the price shall not be
lower than the face value
7.Issuance period:5 year
8.Coupon rate:0%
9.Types, names, monetary values and stipulations of collaterals:NA
10.Use of the funds raised by the offering and utilization plan:
To repay the bank loan
11.Underwriting method:Through auction
12.Trustees of the corporate bonds:Authorize the chairman for decision
13.Underwriter or agent:Authorize the chairman for decision
14.Guarantor(s) for the issuance:NA
15.Agent for payment of the principal and interest:Authorize the chairman
for decision
16.Certifying institution:Paperless share
17.Where convertible into shares, the price and the rules for conversion:
Related conversion rule are in accordance with the local regulation,
conversion detail will be published after approved by the local authority
18.Sell-back conditions:Related conversion rule are in accordance with the
local regulation, conversion detail will be published after approved by
the local authority
19.Buyback conditions:Related conversion rule are in accordance with the
local regulation, conversion detail will be published after approved by
the local authority
20.Reference date for any additional share exchange,
stock swap, or subscription:Related conversion rule are in accordance with
the local regulation, conversion detail will be published after approved
by the local authority
21.Possible dilution of equity in case of any additional
share exchange, stock swap, or subscription:Related conversion rule are in
accordance with the local regulation, conversion detail will be published
after approved by the local authority
22.Any other matters that need to be specified:
(1)After the corporate bond is approved by the local authority, the board
will authorize the chairman to decide the conversion price and related
matter.
(2)The important item for the corporate bonds, including issue price,
conversion price, planned item, price allocation and other matter, are
revised due to the change in regulation or outside environment, the board
will authorize the chairman for decision.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 14 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 June 2022 13:32:05 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.